Related Experiment Video
Updated: Apr 23, 2026
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
Published on: January 29, 2016
Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the
Matthias Freidel1, Sonja Ortler, Alexander Fuchs
1Matthias Freidel, MD, is a Neurologist and Psychiatrist at Neurologische Praxis, Kaltenkirchen, Germany. Sonja Ortler, PhD, is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany. Questions or comments about this article may be directed to Alexander Fuchs, PhD, at alexander.fuchs@novartis.com. He is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany. Sabine Seibert, PhD, is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany. Katrin Schuh, PhD, is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.
Background:
To gain full benefit from disease-modifying therapies such as interferon β-1b, patients with multiple sclerosis (MS) need to adhere to treatment in the long term. Treatment adherence requires high patient satisfaction with treatment and care.
Objectives:
Our aim was to evaluate the satisfaction of patients with MS receiving interferon β-1b Extavia with the patient care program Extracare. Efficacy and safety of treatment were evaluated as secondary objectives.
Methods:
In this prospective, noninterventional 1-year study, data on the satisfaction of 174 patients with MS with Extracare were obtained by questionnaires. Disability and symptom severity as well as patients' reported activity limitations, quality of life, and fatigue were recorded.
Results:
We observed high levels of patients' satisfaction with MS nurses, telephonic care, and information provided by Extracare (values ≤ 1.53 on a Likert scale ranging from 1 [very good] to 6 [insufficient]). Patient reported quality of life (Patient Reported Indices for MS QoL) improved from 11.82 ± 11.36 at baseline to 9.74 ± 10.94 at the end of the study (p = .02), whereas clinical parameters of disease progression remained unchanged. Rate of adverse events was as expected.
Conclusions:
This study provides the basis for further improvements of care programs to increase treatment adherence of patients with MS.
More Related Videos
07:02Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
08:38Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
Published on: April 9, 2012
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
01:30Inhibitors of Viral Protein Synthesis
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF